Drug Insights

How to Effectively Search for Gabapentin on Synapse

31 January 2024
2 min read

Gabapentin is a small molecule drug developed by Pfizer that functions as a CACNA2D2 and Cav2.2 blocker. The drug has been approved for the treatment of various conditions, including anxiety, cough, diabetic neuropathies, epilepsy, fibromyalgia, restless legs syndrome, and seizures. Gabapentin's mechanism of action involves blocking the influx of calcium ions into neurons, thereby reducing their excitability and relieving symptoms such as pain and convulsions. Since its initial approval in 1993, Gabapentin has become a widely prescribed medication for the treatment of these conditions. However, it is important to note that Gabapentin may cause certain side effects, such as drowsiness, dizziness, and difficulty with coordination. Therefore, its use must be closely monitored by healthcare providers, and patients should follow the prescribed dosage and usage guidelines. Click on the image below to begin the exploration journey of Gabapentin through the Synapse database!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Sanofi Plans to Acquire Inhibrx Inc for Rare Disease Candidate
Latest Hotspot
3 min read
Sanofi Plans to Acquire Inhibrx Inc for Rare Disease Candidate
29 January 2024
Sanofi intends to buy Inhibrx, Inc., bringing a promising rare disease candidate targeting Alpha-1 Antitrypsin Deficiency into its portfolio.
Read →
Strand Therapeutics Granted Authorization for Experimental RNA Drug STX-001, Aimed at Addressing Cancerous Growths
Latest Hotspot
3 min read
Strand Therapeutics Granted Authorization for Experimental RNA Drug STX-001, Aimed at Addressing Cancerous Growths
29 January 2024
Strand Therapeutics recently revealed that the FDA has approved its request to commence a Phase 1 clinical trial, marking the initial human study of STX-001.
Read →
Gilead Issues Progress Report for EVOKE-01 Phase 3 Research Trial
Latest Hotspot
3 min read
Gilead Issues Progress Report for EVOKE-01 Phase 3 Research Trial
29 January 2024
Gilead Sciences' EVOKE-01 Phase 3 Trial for Metastatic NSCLC Fails to Achieve Primary Endpoint: A Comparison of Trodelvy and Docetaxel.
Read →
Sandoz declares deal to buy CIMERLI® operations from Coherus, reinforcing its foothold in the US sector
Latest Hotspot
3 min read
Sandoz declares deal to buy CIMERLI® operations from Coherus, reinforcing its foothold in the US sector
29 January 2024
Sandoz Finalizes USD 170 Million Purchase of Coherus BioSciences' Biosimilar Drug CIMERLI* (ranibizumab-eqrn) in the US
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.